Stocks · Health care · Pharmaceutical Preparations

Zymeworks Inc.

ZYME Clue Score44
United States Fiscal year ends December CIK 0001937653 Results filed 6 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Paul Andrew Moore
8 Jan 2024
Chief Scientific Officer
Sell
2,339
$11.22
$26.23K
Christopher Astle
8 Jan 2024
SVP & Chief Financial Officer
Sell
1,431
$11.22
$16.05K
Kenneth Galbraith
8 Jan 2024
Chair & CEO
Sell
5,706
$11.22
$64.00K

What was left out

Form 4 filings counted 94
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 10
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 23
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 6,219,960
History held since 17 Oct 2022